



## REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting

November 10, 2020 08:00 AM EST

ROCKVILLE, Md., Nov. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that two oral presentations will be presented at the American Academy of Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format.

The first presentation will feature data from the RGX-314 Phase I/II subretinal trial for the treatment of wet age-related macular degeneration (wet AMD). Details are as follows:

**Title:** Update on the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

**Presenter:** Dante Pieramici, M.D., Director, California Retina Research Foundation and Partner, California Retina Consultants

**Date/time:** Available on-demand

**Session title:** RET07 – Gene- and Cell-Based Therapies

The second presentation will include data from preclinical studies of suprachoroidal delivery of RGX-314. Details are as follows:

**Title:** Viral and Nonviral Suprachoroidal Ocular Gene Transfer

**Presenter:** Peter A Campochario, M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine

**Date/time:** Friday, November 13, 2020 at 12:36pm PST

**Session title:** RET07V – Gene- and Cell-Based Therapies

### About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### Contacts:

Tricia Truehart  
Investor Relations and Corporate Communications  
347-926-7709  
[ttruehart@regenxbio.com](mailto:ttruehart@regenxbio.com)

Investors:  
Eleanor Barisser, 212-600-1902  
[eleanor@argotpartners.com](mailto:eleanor@argotpartners.com)

Media:  
David Rosen, 212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting-301169240.html>

SOURCE REGENXBIO Inc.